A clinical trial suggests semaglutide significantly reduces abdominal fat in HIV-associated lipohypertrophy, but the potential for adverse events warrant further investigation.
In a recent randomized, double-blind, placebo-controlled study, researchers found reductions in both body weight and knee pain in individuals with obesity and knee osteoarthritis following weekly treatment...
Individuals with prediabetes who achieve a weight loss of at least 5% experience significant improvements in insulin sensitivity and reductions in visceral fat, suggesting that remission of prediabetes can...
Researchers compared people with HIV initiating antiretroviral therapy (ART) with demographically matched people who do not have HIV and did not receive ART to determine whether HIV-specific factors, such...
Researchers evaluated the popular diabetes medication, semaglutide, to determine whether it causes or worsens diabetic retinopathy in patients using the medication. Their findings were presented at AAO 2023...
Researchers compared the effects of once-weekly semaglutide (2.4 mg) with a placebo during a 52-week period in patients with HFpEF and a BMI of 30 or higher.
